PRINCETON, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- In a significant development in cancer therapeutics, Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) has recently unveiled promising safety results for its investigational drug SON-1010 (also known as IL12-F H AB). This announcement was made during a Virtual Investor segment where key members of the management team elaborated on the findings and future steps of their ongoing clinical studies.

During the segment, Raghu Rao, the Interim Chief Executive Officer of Sonnet, and Dr. Richard Kenney, the Chief Medical Officer, discussed the positive safety results observed in the Phase 1b/2a clinical trial. This particular trial, which is examining the effects of SON-1010 in conjunction with atezolizumab, focuses on adult patients suffering from advanced solid tumors, including those with platinum-resistant ovarian cancer (PROC). This study, referred to as SB221, aims to provide insights into how SON-1010 can enhance treatment options for patients battling these difficult-to-treat cancers.

The encouraging safety data presented in this clinical trial is a pivotal milestone for Sonnet, indicating that patients can tolerate this combination therapy without significant adverse effects. Both Mr. Rao and Dr. Kenney expressed optimism about these findings and elaborated on the next steps for advancing the drug's development. They emphasized the importance of continuing to monitor safety and efficacy as the trial progresses and highlighted the company's commitment to addressing the unmet needs of patients with advanced cancers.

For those interested in diving deeper into the discussion, the full segment of the Virtual Investor What This Means presentation, featuring Sonnets management insights, is now accessible online.

About Sonnet BioTherapeutics Holdings, Inc.

Founded with a mission to innovate in the field of oncology, Sonnet BioTherapeutics is a biotechnology company that specializes in developing targeted biologic drugs that act on the tumor microenvironment (TME). The company leverages a proprietary technology platform known as Fully Human Albumin-Binding (F H AB). This advanced system employs a fully human single chain antibody fragment (scFv) designed to bind to and effectively transport therapeutic agents specifically to tumor and lymphatic tissues.

With the F H AB technology, Sonnet aims to optimize the therapeutic window of immune-modulating biologic drugs, ensuring enhanced safety and efficacy. This novel approach paves the way for a range of therapeutic options, including cytokines, peptides, antibodies, and even vaccines. As the field of cancer treatment continues to evolve, Sonnet remains at the forefront, dedicated to developing cutting-edge solutions that could transform patient outcomes.